---
title: "Santhera Pharmaceuticals Reports Strong H1 2025 Growth"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/258624174.md"
description: "Santhera Pharmaceuticals reported a 70% increase in H1 2025 revenue, reaching CHF 24 million, driven by AGAMREE® sales for Duchenne muscular dystrophy. Product sales rose 76%, mainly from Germany, Austria, and the UK. Despite an operating loss of CHF 35.4 million, the company secured CHF 20 million in growth capital. Santhera aims to exceed its 2025 revenue guidance and maintain a cash-flow break-even target for mid-2026, focusing on global expansion and maximizing AGAMREE's market potential."
datetime: "2025-09-24T03:52:08.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/258624174.md)
  - [en](https://longbridge.com/en/news/258624174.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/258624174.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/258624174.md) | [English](https://longbridge.com/en/news/258624174.md)


# Santhera Pharmaceuticals Reports Strong H1 2025 Growth

Santhera Pharmaceuticals Holding AG, a Swiss specialty pharmaceutical company, focuses on developing and commercializing treatments for neuromuscular and pulmonary diseases, with a particular emphasis on rare conditions with high unmet needs. In its half-year 2025 financial report, Santhera highlighted a significant 70% increase in total revenue, reaching CHF 24 million, driven by the strong performance of AGAMREE® for Duchenne muscular dystrophy. The company also reported a 76% rise in product sales, primarily from Germany, Austria, and the UK, and a substantial increase in royalties from licensing partners in the U.S. and China.

Key financial metrics include an operating loss of CHF 35.4 million, attributed to a USD 25 million sales milestone payment, and a decrease in cash and cash equivalents to CHF 18.4 million. Santhera has secured CHF 20 million in additional growth capital to support its global expansion efforts. The company continues to advance its global rollout of AGAMREE, with new distribution agreements in several countries and ongoing pricing and reimbursement discussions in Europe.

Santhera’s strategic focus remains on maximizing the DMD opportunity with AGAMREE, while also exploring potential portfolio expansions through licensing and distribution agreements. The company anticipates exceeding its full-year 2025 revenue guidance and maintains its cash-flow break-even target for mid-2026.

Looking ahead, Santhera is optimistic about its continued growth, driven by strong demand for AGAMREE and ongoing global expansion efforts. The management remains committed to achieving its financial targets and expanding patient access to its treatments worldwide.

## 相關資訊與研究

- [12:30 ETLOUISIANA FISH FRY LAUNCHES NEW VIDEO SERIES WITH EMERIL LAGASSE AND TROMBONE SHORTY CELEBRATING CAJUN FLAVOR](https://longbridge.com/zh-HK/news/281652235.md)
- [Trump weighs broader cabinet shake-up as Iran war pressure grows](https://longbridge.com/zh-HK/news/281681817.md)
- [12:26 ETOdevo deepens Texas presence as WRMC joins](https://longbridge.com/zh-HK/news/281652151.md)
- [11:00 ETUncertainty and caution apparent in new tech employment data, CompTIA analysis finds](https://longbridge.com/zh-HK/news/281648041.md)
- [Omeros Turns Corner With Novo Deal, YARTEMLEA Launch](https://longbridge.com/zh-HK/news/281666535.md)